Posts tagged Driver mutations
Management of Advanced Disease in NSCLC
Management of Advanced Disease in NSCLC

Lung cancer remains the leading cause of cancer death world-wide. This is in part due patients presenting late with disseminated disease and despite recent advances, a limited therapeutic landscape... Despite these advances there remains a significant unmet clinical need with much research needed to elucidate the optimal treatment paradigm to improve response rates, mortality and quality of life for patients with advanced NSCLC. READ ARTICLE

Encyclopedia of Respiratory Medicine (Second Edition) DOI:10.1016/B978-0-08-102723-3.00265-1

Authors: Alice Davies, Martin Forster

Read More
EditorialKirk SmithAdenocarcinoma, Advanced lung cancer, Atezolizumab, Carboplatin, Chemotherapy, Cisplatin, Doxcetaxal, Driver mutations, Gemcitabine, Immunotherapy, Lung cancer, Metastatic lung cancer, Nivolumab, Non small cell, Palliative care, PD1, PDL1, Pembrolizumab, Small cell, Smoking, Smoking cessation, Squamous cell carcinoma, Targeted therapies, Treatment, Vinorelbine
Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens
Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens

Objective: To investigate the mutation status and clinical characteristics of multigene detection in advanced lung adenocarcinoma using cytological specimens... Conclusions: In the study, cytological specimens and biopsy samples have a very high coincidence rate of gene detection. EGFR, ALK and ROS1 mutations were the main driver mutations in patients with advanced lung adenocarcinoma. We speculate that EGFR and ALK are more prone to concomitant mutations respectively and the treatment of advanced lung adenocarcinoma patients with concomitant mutations deserves further study. The rate of KRAS, NRAS, BRAF, PIK3CA, RET and MET exon14 skipping mutation were low but may had a significant impact on the targeted therapy of patients with advanced lung adenocarcinoma. READ ARTICLE

Pathology - Research and Practice DOI:10.1016/j.prp.2020.153036

Authors: Yang Ma, Yun Du, Rui Wang, Xiaokun Ji, Juan Wu, Ying Liu, Xiao Guo, Yan Zhang

Read More
Review PaperKirk SmithLung adenocarcinoma, Cytological, Specimen, ARMS, Driver mutations